Research Article
Circulating Platelet-Derived Microparticles Associated with Postdischarge Major Adverse Cardiac Events in ST-Elevation Acute Myocardial Infarction
Table 1
Characteristics of subjects with STEMI and their comparison based on the occurrence of in-hospital MACE.
| | Characteristics | All subjects n = 101 | In-hospital MACE (+) n = 17 | In-hospital MACE (−) n = 84 | value |
| | Gender (male), n (%) | 95 (94.1) | 17 (100) | 78 (92.9) | 0.321 | | Age (years), mean ± SD | 54.5 ± 8.9 | 55.6 ± 7.9 | 54.3 ± 9.2 | 0.594 | | Dyslipidemia, n(%) | 24 (23.8) | 6 (35.3) | 18 (21.4) | 0.221 | | Diabetes mellitus, n (%) | 24(23.8) | 5 (29.4) | 19 (22.6) | 0.548 | | Ischemic heart disease, n (%) | 22 (21.8) | 3 (17.6) | 19 (22.6) | 0.651 | | Hypertension, n (%) | 45 (44.6) | 11 (64.7) | 34 (40.5) | 0.067 | | Current smoker, n (%) | 62 (61.4) | 11 (64.7) | 51 (60.7) | 0.693 | | Onset (hours), median (IQR) | 4.5(3.0–7.0) | 5 (3.0–7.2) | 4.5 (3.0–7.0) | 0.643 | | Systolic BP (mmHg), mean ± SD | 135.3 ± 25.1 | 130.2 ± 18.8 | 136.3 ± 26.1 | 0.368 | | Diastolic BP (mmHg), mean ± SD | 83.2 ± 13.8 | 82.0 ± 13.8 | 83.4 ± 13.9 | 0.702 | | Heart rate (x/min), mean ± SD | 79.2 ± 17.6 | 91.1 ± 19.7 | 76.8 ± 16.2 | 0.002 | | Anterior STEMI, n (%) | 55 (54.5) | 12 (70.6) | 43 (51.2) | 0.328 | | Killip class ≥2 | 14 (13.9) | 14 (82.6) | 0 (0) | <0.001 | | Revascularization | | | | 0.123 | | Primary PCI | 52 (61.2) | 11 (64.7) | 41 (48.8) | | | Fibrinolysis | 33 (38.8) | 2 (11.8) | 31 (36.9) | | | Vessel disease | | | | 0.726 | | 1 vessel disease | 25 (38.5) | 4 (23.5) | 21 (25.0) | | | 2 vessel disease | 19 (29.2) | 4 (23.5) | 15 (17.9) | | | 3 vessel disease | 18 (27.7) | 4 (23.5) | 14 (16.7) | | | Any + left main disease | 3 (4.6) | 1 (5.9) | 2 (2.4) | | | Culprit vessel | | | | 0.164 | | Left anterior descendent | 41 (63.1) | 11 (64.7) | 30 (35.7) | | | Right coronary artery | 22 (33.8) | 2 (11.8) | 20 (23.8) | | | Left circumflexus | 2 (3.1) | 0 (0) | 2 (2.4) | | | Intervention | | | | 0.332 | | Drug-eluting stent | 62 (95.4) | 13 (76.5) | 49 (58.3) | | | Bare metal stent | 3 (4.6) | 0 (0) | 3 (3.5) | | | Haemoglobin (g/dL) | 13.9 ± 1.6 | 13.6 ± 1.6 | 14.0 ± 1.6 | 0.299 | | Leucocytes (×103/mm3) | 13.4 ± 3.6 | 14.7 ± 5.2 | 13.2 ± 3.2 | 0.239 | | Platelets (×103/mm3) | 268.9 ± 82.3 | 273.6 ± 75.8 | 267.9 ± 83.9 | 0.796 | | Creatinine (mg/dL) | 1.2 ± 0.4 | 1.4 ± 0.4 | 1.2 ± 0.4 | 0.034 | | Urea nitrogen (mg/dL) | 15.5 ± 6.8 | 18.0 ± 9.9 | 15.0 ± 5.9 | 0.240 | | Random glucose (mg/dL) | 168.2 ± 77.4 | 174.5 ± 91.6 | 166.9 ± 74.8 | 0.722 | | Clopidogrel | 101 (100) | 17 (100) | 84 (100) | NA | | Acetylsalicylic acid | 101 (100) | 17 (100) | 84 (100) | NA | | ACEI/ARB | 68 (67.3) | 14 (82.4) | 54 (64.3) | 0.147 | | Beta blockers | 61 (60.4) | 11 (64.7) | 50 (59.5) | 0.690 | | Furosemide | 16 (15.8) | 11 (64.7) | 5 (6.0) | <0.001 | | Heparin | 64 (63.4) | 10 (58.8) | 54 (53.4) | 0.670 |
|
|
n = 85 subjects; n = 65 subjects. BP: blood pressure; STEMI: ST-elevation myocardial infarction; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin-receptor blocker: NA: not applicable. |
